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Review

Chronic Lymphocytic Leukemia: A Review of
Front-line Treatment Options, With a Focus on
Elderly CLL Patients
Alma O’Reilly,1 James Murphy,1 Sarah Rawe,2 Mary Garvey1
Abstract
Chronic lymphocytic leukemia (CLL) remains the most prevalent form of leukemia in the Western world, with no cure to
date. Ongoing and essential research into this heterogeneous disease has led to a number of new treatment options
becoming available to CLL patients in the past decade. The present review presents the recent developments in the
ﬁeld of CLL treatment, with the main focus on elderly patients and CLL patients with coexisting comorbidities. The
review discusses the current treatment regimens that provide the most promising outcomes for patients in this
subgroup, with a number of important clinical trials summarized. These clinical trials, which have investigated
promising single-agent therapies or combination therapies, are discussed, with an emphasis on the efﬁcacy and
tolerability for patients aged  65 years. Also, the misrepresentation of the true CLL population in many clinical trials
and the need for better guidelines for participant inclusion criteria to provide a more realistic and accurate study
population are noted.
Clinical Lymphoma, Myeloma & Leukemia, Vol. -, No. -, --- ª 2018 Elsevier Inc. All rights reserved.
Keywords: CLL clinical trials, Current treatment standards, Monoclonal antibodies, Older patients, Small molecules

Introduction
Approximately 10% of all cancer cases are blood cancers, with a
new diagnosis every 3 minutes in the United States. In Ireland,
blood cancer cases are the fourth most common cause of cancerrelated deaths.1,2 Blood cancer is a broad term used to classify
any cancer that affects the cells of the blood or organs where blood
cells develop (ie, bone marrow and lymphatic system). Leukemia,
cancer of the white blood cells, is one of the most common types of
blood cancer.3 Chronic lymphocytic leukemia (CLL) is the most
prevalent leukemia in adults in the Western world and accounts for
25% to 30% of all leukemia types.4 The incidence rate was 4.83/
100,000 people in the United States from 1975 to 2014.5 The
disease typically affects older people and is rare in those aged < 50
years.6,7 With an ever-aging population due to improved health care
and better lifestyles, the average age at the diagnosis for CLL has
increased by 6 years during the past decade. The median age at
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diagnosis was 65 years in the early 1990s,8,9 which has increased to
70 years in the present day.10 Therefore, the need to develop better
tolerated treatment options for elderly CLL patients is constant and
urgent.
CLL is characterized by a relentless accumulation of CD5þ B
lymphocytes in the blood, bone marrow, and secondary lymphoid
organs, lymph nodes, and spleen.4 This form of leukemia begins in
the bone marrow and affects the lymphocytes. These cells do not
mature properly and are unable to perform their immunologic
function in ﬁghting infection. The cells also survive longer than
needed, eventually building up in the blood and crowding out
healthy cells.11
CLL is a heterogeneous disease; thus, in some cases, the disease
progresses so slowly treatment is not required, but in others, a more
aggressive form of the cancer develops. In many cases, the slow
progressive nature of the disease means that one third of patients
with CLL never need treatment, with a “watch and wait” approach
the standard management for early-stage CLL.6 Once progression
has occurred, treatment is required. However, for other patients, the
disease can be more aggressive, with poor prognostic factors, leading
to fast progression and the need for immediate treatment. A number
of genetic factors indicating a more aggressive form of CLL include,
but are not limited to, deletion of the short arm of chromosome 17
[del(17p)], deletion of the long arm of chromosome 11 [del(11q)],
and a mutation of the tumor suppressor gene for tumor protein
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53 (TP53). TP53 mutation results in a nonfunctional p53 protein,
a protein that plays a key role in signaling the cell to undergo
apoptosis.12 In > 80% of patients presenting with del(17p), a TP53
mutation will coexist on the other allele.13,14 In the case of del(11q),
the ATM gene will be mutated, another gene important for activation of the apoptosis pathway. The mutation and deletion of such
genes leads to nonfunctional proteins that play an important role in
inducing apoptosis in the cell, which can severely impair the efﬁcacy
of chemotherapy drugs.15
Chemoimmunotherapy is now the current standard of treatment
for CLL patients in general good health. FCR (ﬂudarabine, cyclophosphamide, rituximab) is recommended for ﬁt patients aged < 65
years as ﬁrst-line treatment, and patients aged > 65 years are
typically recommended to receive BR (bendamustine, rituximab).
The prevalence of CLL in older people has led to a number of
additional factors that should be considered when choosing a course
of treatment. Also, many older patients with comorbidities are
unsuitable for intense chemoimmunotherapy.
Because older CLL patients can differ dramatically in their
physiologic age and pathologic conditions (eg, comorbidities and
geriatric syndromes), various treatment options must be available
that can cater to both patient-related and disease-related risk factors.
Owing to an age-related decline in hematopoietic stem cells, which
are necessary for the production of new blood cells by the body,
chemotherapy-related myelotoxicities will be more frequent in older
patients with CLL. This is a high-risk factor, because the resulting
infections or anemia could negatively affect a patient’s current
comorbidities and lead to treatment-related morbidity or
mortality.16

Current Front-line Treatment
Options for Elderly CLL Patients
Monoclonal Antibodies
Anti-CD20 antibodies are a group of compounds that are added
to chemotherapy regimens to provide a patient with chemoimmunotherapy, a treatment option that has become the reference
standard treatment of CLL for ﬁt patients.
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Rituximab. Since the approval of rituximab in 1997, the type I
monoclonal anti-CD20 antibody has been used in the treatment of
numerous illnesses, including follicular B-cell lymphoma, aggressive
lymphoma, and CLL.17 Its mode of action involves binding to the
CD20 antigen on the surface of B cells. Although some studies
showed it to be effective as monotherapy,18 other study found the
antibody had a much greater effect when used in combination with
other chemotherapy agents.19 However, the chemotherapeutic
agent with which rituximab is combined must be considered carefully, because the adverse effects of some treatment options will not
be tolerable by older patients or patients with comorbidities.
FCR is the reference standard treatment for CLL patients aged
< 65 years with otherwise good health and low-risk prognostic
factors and who have not received previous treatment. Some older
patients with good health and favorable prognostic factors might be
suitable for FCR. However, most patients aged > 65 years and
patients with comorbidities will not tolerate FCR well. Myelosuppression, a side effect of therapy, causes a decrease in the function of
the bone marrow, which leads to low counts of red blood cells,

Clinical Lymphoma, Myeloma & Leukemia Month 2018

white blood cells, and platelets. It is one of the main side effects
leading to the discontinuation of FCR treatment.20 Myelosuppression and its complications after FCR treatment are more
frequent in older patients; thus, a different course of treatment with
fewer side effects has been more favorable for this group.21
CLL10 Study

Patients who are not suitable for FCR as front-line treatment
because of age and/or comorbidities have other treatment options
available that are better tolerated. The CLL10 study, a comparative
study by Eichhorst et al,22 investigated FCR versus BR as a ﬁrst-line
treatment option for patients with advanced CLL and found BR to
be a better tolerated treatment option for older CLL patients, with
similar efﬁcacy. Their study included 561 treatment-naive patients
with active CLL and in good physical health. The patients were
divided into 2 groups: the FCR group (282 patients) and the BR
group (279 patients). The age range of the study was 33 to 81 years
(median, 61.5 years), and patients with del(17p) were excluded.22
This trial, and all the trials discussed in this reveiw, are summarized in Table 1. As expected, the FCR group experienced signiﬁcantly longer progression-free survival (PFS), with a median of 57.6
months compared with 42.3 months for the BR group.34 When
PFS was analyzed by dividing the population into 2 groups stratiﬁed
by age (< 65 years vs. > 65 years), a difference was noted. In the
younger age group, a signiﬁcant difference was seen in the median
PFS for the 2 treatment arms, with 38.5 months for BR and 53.6
months for FCR. However, when the older age group was analyzed,
no signiﬁcant difference was found.22 This ﬁnding, the ﬁnding that
FCR treatment was more toxic in the elderly patient group (71% of
patients experienced grade 4 adverse effects resulting in lifethreatening consequences and/or hospitalization35 compared with
41% in the BR group), and the greater occurrence of therapy-related
myeloid leukemia/myelodysplastic syndrome in the older patient
group in the FCR arm, showed that BR is a much better front-line
chemoimmunotherapy option for elderly CLL patients not suitable
for FCR.22,36,37
Rituximab and Hyaluronidase Human

A new development in the treatment of CLL with FCR has
recently been approved by the Food and Drug Administration
(FDA). In June 2017, rituximab and hyaluronidase human (RHH)
was approved for the treatment of 3 blood cancers: follicular lymphoma, diffuse large B-cell lymphoma, and CLL.38 Human hyaluronidase is an endoglycosidase, an enzyme that cleaves speciﬁc
internal glycosidic linkages of oligosaccharides and polysaccharides,
leading to a release of oligosaccharides.39 It increases the rate of
dispersion and absorption of drugs coadministered by subcutaneous
injection. The approval of this new product has meant that rituximab can be administered in 5 to 7 minutes, a greatly reduced time
compared with the standard intravenous administration, which requires several hours. Also, RHH can be used for both treatmentnaive and previously treated CLL patients when combined with
FC (ﬂudarabine, cyclophosphamide).38,40 However, no clinical information is yet available on the use of bendamustine combined
with RHH.
Obinutuzumab. Obinutuzumab, a glycoengineered type II antiCD20 monoclonal antibody, also referred to as GA101, has
shown great promise for elderly CLL patients with comorbidities
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Table 1 Summary of Important Clinical Trials for Determination of Superior Treatment Regimens for Elderly CLL Patients
Trial Name

Treatment

Patients, n

Median Age, y

Patient Group

CLL1022
CLL1123,24
GREEN25
COMPLEMENT-126

FCR vs. BR
GþCB, CB, RþCB
G-Mono, GþFC, GþCB, GB
OþCB, CB

561
589
971
447

61.5
73
66
69

COMPLEMENT-227
RESONATE28
RESONATE-229
HELIOS30
CLL1431

OþFC, FC
I, O
I, CB
IþBR, BR
VþG, GþCB

365
391
269
578
445

61.5
67
73
63.5
NR yet

Untreated CLL; del(17p) excluded
Untreated CLL; coexisting health issues
R/R CLL and untreated CLL
Untreated CLL; not suitable for ﬂudarabinebased treatment
R/R CLL
R/R CLL
Untreated CLL; 65 years & older
R/R CLL
Untreated CLL; coexisting health issues

Superior Treatment for
Age > 65 y
BRa
GþCB
Ongoingb
OþCB
NAc
Ibrutinib
Ibrutinib
NAd
Ongoinge

Abbreviations: BR ¼ bendamustine, rituximab; CB ¼ chlorambucil; CLL ¼ chronic lymphocytic leukemia; del(17p) ¼ deletion 17p; FCR ¼ ﬂudarabine, cyclophosphamide, rituximab; GþCB ¼
obinutuzumab, ofatumumab; GþFC ¼ obinutuzumab, ﬂudarabine, cyclophosphamide; GB ¼ obinutuzumab, bendamustine; G-Mono ¼ obinutuzumab monotherapy; I ¼ ibrutinib; NA ¼ not available;
NR ¼ not reported; O ¼ ofatumumab; OþCB ¼ ofatumumab, chlorambucil; OþFC ¼ ofatumumab, ﬂudarabine, cyclophosphamide; RþCB ¼ rituximab, chlorambucil; R/R ¼ relapsed/refractory;
VþG ¼ venetoclax, obinutuzumab.
a
Although low median age, results for those aged > 65 years were analyzed.
b
Estimated completion date October 2018.32
c
Because of low median age, trial not suitable for determining superior regimen for those aged > 65 years.
d
Because of low median age, trial not suitable for determining superior regimen for those aged > 65 years.
e
Estimated completion date September 2021.33

and was approved by the FDA in November 2013 in combination
with chlorambucil for the treatment of CLL.41,42 Obinutuzumab
showed increased direct cytotoxicity and greater antibodydependent cellular cytotoxicity.43 It was proved to have superior
antitumor activity compared with rituximab in preliminary studies,
resulting in complete tumor remission and increased overall survival
(OS).44 Numerous clinical trials were conducted to determine the
safety and effectiveness of obinutuzumab in recent years. Phase I
and II clinical trials evaluated the effectiveness of obinutuzumab as
monotherapy and showed promise for heavily pretreated CLL patients. These trials showed obinutuzumab was a more effective
monotherapy than rituximab and ofatumumab, with greater efﬁciency of B-cell depletion.45,46
CLL11 Study

A phase III clinical trial, the CLL11 study, compared the treatment options of obinutuzumab combined with chlorambucil
(GþCB), against chlorambucil alone (CB) and rituximab plus
chlorambucil (CBþR). The CLL11 trial included 589 patients with
previously untreated CLL (summarized in Table 1). For the ﬁrst
stage, the patients were divided into 3 groups, at a 2:2:1 ratio (238
patients in the GþCB group, 233 patients in the RþCB group, and
118 patients in the CB group). The second stage included 192
additional patients, randomly grouped into either the GþCB or
RþCB arm.23,41 The median age of the trial population was 73
years, with coexisting comorbidities a part of the inclusion criteria
(total Cumulative Illness Rating Scale [CIRS] score > 6 and/or
creatinine clearance [CrCl] < 70 mL/min).23 A recent update from
that study showed that GþCB almost doubled the median PFS
compared with the RþCB combination, extending the PFS to 29.2
months compared with 15.4 months.24 According to Owen,47 in
many parts of Canada, BR is the preferred treatment option when
tolerable. However, for older patients, unﬁt for the more aggressive
treatment of BR, the GþCB combination is now a commonly used

regimen in most treatment centers.47 However, no clinical trial has
yet compared BR and GþCB.
The GREEN Study

An ongoing phase IIIB clinical trial, called the GREEN study (see
Table 1), is comparing the safety of as obinutuzumab as monotherapy (G-Mono) or combined with different chemotherapy regimens in both untreated patients and patients with relapsed/
refractory (R/R) disease (ie, patients with disease no longer
responding to treatment). The combination treatment options
analyzed were GþFC for ﬁt patients only (ie, CIRS score of  6
and CrCl of  70 mL/min), GþCB for unﬁt patients only (CIRS
score > 6 and CrCl < 70 mL/min) or GþB (obinutuzumab,
bendamustine) for any patient.25 The study is currently active, with
an estimated completion date of October 2018.32 However, the
results of the primary analysis of the trial were presented at the 59th
annual meeting and exposition of the American Society of Hematology in December 2017.
The trial population is 971 patients, divided into 3 patient
groups: 339 ﬁt; 291 unﬁt, and 341 with R/R disease, with a median
age of 66 years. The initial report concluded that toxicities were
“manageable and no new safety signals were identiﬁed.”25 The
median observation time for the study to date was 24.5 months.
The most frequent adverse effects reported across all treatment
options were neutropenia (58.4%), pyrexia (32%), thrombocytopenia (31.2%), nausea (27.8%), and anemia (23.7%), with no
signiﬁcant difference in the 3 patient groups; 80.3% of the patients
developed grade  3 adverse effects, with neutropenia, thrombocytopenia, anemia, and pneumonia the most frequent. A similar
frequency of grade  3 adverse effects were experienced by all 3
patient groups. However, serious adverse effects (neutropenia,
pneumonia, and febrile neutropenia) occurred more frequently in
the unﬁt patient group (58.8%) than in the ﬁt patient group
(43.7%).25
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A comparison of treatments showed the lowest death rate in the
GþFC patient group (4.7%), followed by the GB group (7.8%),
GþCB group (7.9%), and G-Mono group (8.7%). However, the
GþFC patient group experienced the greatest rate of adverse effects
(87.6%) compared with the other treatment groups (G-Mono,
75.4%; GþCB, 76.3%; and GB, 79.7%). The occurrence of grade 
3 adverse effects was also signiﬁcantly greater, with a greater incidence
of infection in the GþFC group (70.5%) than in the other treatment
groups (G-Mono, 49%; GþCB, 53%; GB, 52.6%).25
With the initial ﬁndings of the study showing acceptable safety
data in line with data for previously reported obinutuzumab-based
treatments, the forthcoming results should help determine the
best obinutuzumab treatment combinations for patients of different
ﬁtness groups and also for R/R patient groups.
Ofatumumab. Ofatumumab, also known as HuMax-CD20, is a
fully human type I anti-CD20 monoclonal antibody that targets a
distinct small-loop epitope on the CD20 molecule.48 Preliminary
studies showed greater levels of cytotoxicity with ofatumumab
compared with rituximab.49 Early clinical trials focused on the
effectiveness of ofatumumab as a single-agent therapy for patients
with R/R disease. These trials concluded that ofatumumab is a welltolerated, effective treatment for patients with R/R CLL with a poor
prognosis.48,50 After another clinical trial, by Lemery et al,51 which
analyzed ofatumumab as a treatment of CLL refractory to ﬂudarabine and alemtuzumab, the FDA granted accelerated approval of
ofatumumab for R/R CLL.
COMPLEMENT Studies

A phase III clinical trial (COMPLEMENT-1) by Hillmen et al26 in
2015 studied ofatumumab combined with CB (OþClb) versus CB
alone in the treatment of treatment-naive CLL patients. The study
contained 447 patients with active CLL who were unsuitable for
ﬂudarabine-based treatment; the median patient age was 69 years.
The OþCB group had signiﬁcantly longer PFS at 22.4 months
compared with 13.1 months for the CB group. Although adverse
effects were more frequent in the OþCB arm of the study (50% vs.
43% CB), the trial found that front-line treatment with OþCB for
elderly patients and patients with comorbidities was an important
treatment option for those not suitable for more intense regimens.26
The results of another phase III clinical trial, COMPLEMENT2, considered ofatumumab combination with FC (OþFC) versus
FC alone for treatment of relapsed patients were reported by Robak
et al.27 The study, consisting of 365 patients with a median age of
61.5 years, showed that with the OþFC arm of the study, the
median PFS of patients was signiﬁcantly improved at 28.9 months
for OþFC versus 18.8 months for FC alone.27 Of the patients,
74% experienced grade  3 adverse effects in the OþFC group
versus 69% for the FC group. The study concluded that OþFC
combination therapy had manageable safety, with increased
PFS.27,52 A reduced occurrence of thrombocytopenia and anemia
was seen with in the OþFC treatment option compared with FC
(grade  3 thrombocytopenia, 14% vs. 25%; and anemia, all
grades, 20% vs. 30%), indicating that ofatumumab might help to
prevent myelosuppression.27
Although no direct comparative study is yet available of OþFC
and FCR therapy, an indirect comparison of the COMPLEMENT-
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2 trial against another phase III trial of previously treated CLL
patients who received either FCR or FC (population size, 552 patients; median age, 62.5 years) has indicated that grade  3 adverse
effects were comparable with the 2 treatment options (COMPLEMENT trial: OþFC, 74%; FC, 69%; FCR vs. FC trial: FCR, 80%;
FC, 74%).27,53 However, a direct comparison trial of OþFC versus
FCR is needed to conﬁrm these suggestions and to help determine
which treatment option is more efﬁcient and tolerable. If ofatumumab were found to reduce the risk of myelosuppression with FC
treatment, this could give more elderly patients a chance of receiving
FC-based therapy.

Small Molecules
Three novel agents have recently been approved for treatment of
CLL in the United States, 2 kinase inhibitors, ibrutinib and idelalisib, and the Bcl-2 inhibitor venetoclax. No guidelines were available regarding the superiority of the 3 compounds until a recent
study by Mato et al54 in 2017. Their study, which included 683
patients, identiﬁed ibrutinib as superior to idelalisib. Where KIs
were not effective, venetoclax appeared superior to chemoimmunotherapy combinations. Also, treatment with venetoclax after ibrutinib failure was recommended as a superior treatment
option to idelalisib.54
Ibrutinib. Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, was
originally approved by the FDA in 2014 for the treatment of CLL
patients who had received  1 other treatment and for patients with
del(17p). It was granted further approval by the FDA as a ﬁrst-line
treatment of CLL in March 2016.55 The compound, which is an
effective treatment for patients with poor prognostic factors, has also
shown promising results for the treatment of elderly CLL patients.56-58
Ibrutinib acts downstream of the B-cell receptor pathway,
inhibiting BTK, a critical component of the B-cell receptor
signaling pathway, which is only essential for B cells; therefore,
inhibition of this kinase is not fatal.59 Both in vitro and in vivo, this
BTK inhibitor reduces the ability of microenvironment-induced
survival and proliferation of CLL cells.59 Ibrutinib as front-line
therapy for CLL patients with the unfavorable del(17p) resulted
in more effective responses than those reported with FCR treatment
and is now the standard front-line treatment for this patient
group.56,60 It is also an alternative treatment option to chemoimmunotherapy for elderly patients.61,62
RESONATE Study

This phase III clinical trial, investigated the use of ibrutinib or
ofatumumab as a treatment option for pretreated CLL patients
unsuitable for chemoimmunotherapy.28 The inclusion criteria for
the study were patients who had received  1 previous treatment
that had resulted in a short remission time because of one of the
following: age > 70 years, coexisting illnesses, or del(17p) CLL. The
median age was 67 years, with a study population of 391 patients.
The ﬁndings of the RESONANTE study showed ibrutinib to be
superior to ofatumumab in all subgroups analyzed, including R/R
patients, patients with del(17p) and patients aged > 65 years. Thus,
the investigators concluded that ibrutinib as a monotherapy is an
excellent treatment option for CLL patients unsuitable for
immunochemotherapy.28
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Another phase III clinical trial (RESONATE-2) by Burger et al62
in 2015 showed ibrutinib to be a superior treatment regimen to CB
in elderly patients. The study included 269 CLL patients aged > 65
years (median age, 73 years) and showed ibrutinib achieved significantly longer PFS than CB. At a median follow-up of 18.4 months,
the median PFS had not been reached for ibrutinib versus 18.9
months for CB. The OS with ibrutinib was signiﬁcantly improved
compared with the OS with CB. At 24 months, the corresponding
OS rates were 98% and 85%.62 A follow-up study of the
RESONATE-2 study by Barr et al29 showed increased PFS for
ibrutinib compared with CB at 24 months (89% vs. 34%, respectively). It has been proved that ibrutinib as monotherapy is a
treatment option without the use of traditional chemotherapy drugs
that can provide a ﬁrst-line treatment option for elderly patients not
suitable for FCR.
An indirect comparison of ibrutinib as monotherapy and BR
therapy was conducted from the results of 2 phase III clinical trials,
the RESONATE28 and HELIOS30 (a study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed
or refractory chronic lymphocytic leukemia or small lymphocytic
lymphoma) trials, by Hillmen et al63 in 2015. The RESONATE
trial (discussed previously) had a study population of 391 patients,
with a median age of 67 years.28 The HELIOS trial included a
population of 578 patients with a median age of 63.5 years.30 The
HELIOS trial investigated ibrutinib combined with BR (IþBR)
versus BR alone as a treatment regimen for previously treated patients.30 Because these 2 trials had populations with different patient
characteristics (eg, age) and exclusion of high-risk factor groups such
as del(17p) in the HELIOS trial, the group used patient-level data
from both studies to complete the cross-comparison. The results of
the cross-comparison of the 2 trials suggested single-agent ibrutinib
was a superior treatment option to BR treatment and that the
combination regimen of IþBR had comparable results for PFS and
OS compared with ibrutinib alone.63 However, a direct comparison
of ibrutinib monotherapy and IþBR combination therapy is needed
to determine the superiority of the 2 regimens.
In the HELIOS trial, the combination of IþBR for patients
suitable for BR therapy resulted in signiﬁcantly improved outcomes
with no new safety signals and a manageable safety proﬁle. This
suggests that IþBR could be a superior treatment regimen for
elderly patients eligible for BR therapy.30
Idelalisib. Idelalisib is an orally available, highly speciﬁc, and
reversible kinase inhibitor that targets the phosphatidylinositol 3
kinases (PI3Ks).64 PI3Ks are essential for the activation, proliferation, migration, and survival of B cells, along with their homing and
retention in lymphoid tissue.65 Idelalisib (Zydelig) has been shown
to be an effective treatment option for patients with R/R CLL, even
patients with poor prognostic factors.66 A phase II clinical study
reported in 2014 by Zelenetz et al67 of idelalisib as monotherapy for
previously untreated elderly patients (age > 65 years) showed
encouraging results with a manageable safety proﬁle. Another phase
II trial by O’Brien et al68 in 2015 showed promising results for a
combination regimen of idelalisib plus rituximab for treatmentnaive elderly patients (median age, 71 years). In that trial, the
overall response rate for patients with a del(17p) or TP53 mutation

was 100%, and the overall response rate for unmutated immunoglobulin heavy chain variable genes, another poor progression factor,
was 97%. After a 36-month period, the PFS rate was 83%.68 The
advantage of this combination compared with either agent as
monotherapy was the shortened duration of lymphocytosis (high
lymphocyte count) and improved PFS times, response rates, and
OS.69 These ﬁndings revealed the excellent potential for idelalisib as
a treatment regimen for elderly patients and patients with poor
prognostic factors.
However, further investigations have raised concern about idelalisib, and it is not thought to be a safe monotherapy for treatmentnaive patients. Idelalisib was approved by the FDA in July 2014 for
combination treatment with rituximab for R/R CLL but not for use
as a ﬁrst-line treatment option for CLL.70 However, since approval
by the FDA, at least 6 clinical trials involving idelalisib were stopped
because of severe adverse effects and toxicity leading to death.71 In
March 2016, the FDA announced they were reviewing the ﬁndings
of the clinical trials and alerted health care professionals of
“increased rates of adverse effects” with idelalisib.72 At present, the
FDA is reviewing the results of the clinical trials and has warned of
the increased rates of adverse events, including death.71
Venetoclax. Venetoclax, also referred to as ABT-199, is an antiapoptotic Bcl-2 inhibitor that received accelerated US FDA accelerated approval in 2016 for the treatment of relapsed del(17p) CLL,
because it was proved to be highly effective in the treatment of R/R
CLL.73,74 Venetoclax has been proved to be highly active in patients
with poor prognostic factors such as del(17p), with preclinical data
showing the ability of the inhibitor to kill CLL cells and spare
healthy T cells, granulocytes, and platelets.75 Bcl-2 is a prosurvival
protein. Its function is to inhibit the actions of proapoptotic proteins such as BAX/BAK. When Bcl-2 is inhibited in the cell, the
activation of such proapoptotic proteins is triggered. The Bcl-2
protein is known to be critical for B-cell survival, and proteins
such as Bcl-xL are more important for the survival of other lymphocytes such as T cells and granulocytes. Thus, venetoclax is selective to B cells. However, the compound is as potent on non-CLL
B cells as on CLL B cells.75 Venetoclax has been shown to produce
promising results both as monotherapy and combined with
rituximab.74,76
Although venetoclax has been shown to be an efﬁcient treatment
for R/R CLL patients, the use of the Bcl-2 inhibitor in a treatment
regimen for elderly CLL patients is not clear. A number of clinical
trials are underway assessing the efﬁcacy and safety of venetoclax as
monotherapy and in combination therapies (V [venetoclax]þBR for
R/R and previously untreated patients, GþV vs. GþCB for previously untreated patients, VþGþI in R/R and previously untreated
patients, and VþI in treatment-naive patients).77
CLL14 Trial

One such trial, the CLL14 study, focusing on treatment-naive
CLL patients with coexisting medical issues, is a phase III study
of the efﬁcacy and safety of VþG combination therapy versus
GþCB. The CLL14 trial is currently active and has 445 participants enrolled.31 Although no results have yet been reported, a runin safety phase was conducted. That phase included 13 patients with
a median age of 75 years; it found no initial safety risks, and the

Clinical Lymphoma, Myeloma & Leukemia Month 2018

-5

Front-line Treatment for Elderly CLL Patients
CLL14 trial opened in August 2015.78 The anticipated results from
this study, summarized in Table 1, and from the numerous other
clinical trials actively investigating the safety and efﬁciency of venetoclax as both monotherapy and in combination therapies will help
advise health care professionals on the uses of these regimens for
elderly patients with active CLL.

Upcoming Clinical Trials
According to the US National Library of Medicine, almost 200
clinical trials are currently recruiting CLL patients.79 These trials are
investigating numerous novel treatment options and new combinations of currently approved therapies with the purpose of further
improving the progress of CLL treatment. However, a common
misrepresentation of the CLL population exists in a large number of
clinical trials. Although the median age at diagnosis for the disease has
been 70 years, with many patients not requiring immediate treatment,
the average age in many clinical trials has been < 65 years,22,27,30 with
some studies setting the age criterion at 18 to 70 years and thereby
preventing patients aged > 70 years from participating in the trial.80 In
addition to age, the exclusion criteria for many studies prohibit the
recruitment of patients with common health issues, which are representative of the overall CLL population. The Eastern Cooperative
Oncology Group (ECOG) performance status is a scale from 0 to 5
used to measure a patient’s level of function and ability to conduct daily
tasks.81 For a large number of clinical trials, an ECOG level of 0 to 2
has been accepted for inclusion in the study (an ECOG performance
status of 2 indicates the patient is ambulatory and capable of all self-care
but unable to carry out any work activities and is up and about for
> 50% of waking hours).81 Patients with an ECOG status of  3 (with
3 indicating the patient is capable of only limited self-care and is
conﬁned to a bed or chair for > 50% of waking hours) are often
excluded from participation in clinical trials, although a high proportion of CLL patients might be at this ECOG level.82,83 A study of
small-cell lung cancer, which considered the uptake and tolerance of
chemotherapy for patients aged  75 years, found that 39% of patients
aged 75 to 79 years were considered to be at ECOG level 3 or 4.84

Conclusion
Although signiﬁcant progress has been made in the ﬁeld of CLL
treatment in the past 2 decades, CLL remains an incurable disease.
The available options for patients with poor prognostic factors and
elderly patients with comorbidities are increasing rapidly, with
better tolerated therapies and more effective outcomes. However,
elderly patients and patients with coexisting comorbidities, which
account for a high percentage of the CLL population, are still
signiﬁcantly underrepresented in the ﬁeld of clinical research. This
has left many unanswered questions and insecurities when choosing
the most effective and best-tolerated regimens for patients in these
categories. The overall CLL population should be better represented
in clinical trials with guidelines to ensure that trial participants are
chosen as a true reﬂection of the disease characteristics needed to
provide more accurate information on the treatment regimens.
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